Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Depression, Interpersonal Relations
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder is a highly prevalent, recurrent, and debilitating disease, the third cause of years of lost life in the world, and it may be the most common disease in 2030, according to the World Health Organization (WHO). Furthermore, it's also related to decreased quality of life and high mortality. Interpersonal psychotherapy (IPT) is a first-line treatment and can also be used for the prevention of depression. This randomized controlled clinical trial is planned to have 50 participants randomized between an interventional and a control group (waiting list). Our study covers young adults (18 to 24 years old) with depression. Participants will be invited by social media to undergo treatment in an IPT group. The intervention group will be separated into groups with up to 10 participants, with a weekly meeting for eight weeks. The intervention will focus on interpersonal relationships within the model of IPT and will be held by a university student and a doctor trained in IPT.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Interpersonal psychotherapy — Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.

Primary Outcomes

  • Hospital Anxiety and Depression Scale (HADS) (Pre-treatment, Week 1 to 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 24 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital de Clinicas de Porto Alegre
Contact Information
Study Contact:
Neusa Sica da Rocha, PhD
55(51) 3359-8000
nrocha@hcpa.edu.br
Neusa Sica da Rocha, PhD
(5551) 3359-8000
nrocha@hcpa.edu.br
Clinical Hospital for Porto Alegre
Interventions
  • Behavioral: Interpersonal psychotherapy — Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
Study Locations (1 sites)
Clinical Hospital for Porto Alegre, Porto Alegre, Rio Grande do Sul 90035-903 Brazil
Eligibility Criteria
Inclusion Criteria: * Young adults (between 18 and 24 years old) * Young adults who work, live or study in Porto Alegre * PHQ ≥ 5 - without suicide ideation Exclusion Criteria: * Maniac or hypomanic episode * Psychotic Syndrome * Substance Abuse * Suicide Risk or Ideation
Conditions Long COVID, Major Depressive Disorder, M...
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Other: [11C]DTBZ PET scan — One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
  • Other: [18F]SDM8 PET scan — One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
  • Other: MRI scan — One MRI scan

Primary Outcomes

  • Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND) (within 3 to 4 weeks after initiation of screening)
  • Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT) (within 3 to 4 weeks after initiation of screening)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-22
Completion: 2028-09-10
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Addiction and Mental Health
Principal Investigators:
  • Jeffrey Meyer, M.D., PhD (PRINCIPAL_INVESTIGATOR) - Centre for Addiction and Mental Health
Contact Information
Study Contact:
Karida Liu
416-535-8501
liuyuhan0830@gmail.com
Jeffrey Meyer
416-535-8501
jeffrey.meyer@utoronto.ca
Yuhan Liu
(416) 535-8501 ext. 39674
yuhan.liu@camh.ca
Centre for Addiction and Mental Health
Interventions
  • Other: [11C]DTBZ PET scan — One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
  • Other: [18F]SDM8 PET scan — One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
  • Other: MRI scan — One MRI scan
Study Locations (1 sites)
Centre for Addiction and Mental Health, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: * New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined. * Age 18 to 75. * Good general physical health with no active medical conditions based on self-report (except migraine or PASC). Exclusion Criteria: * Use of antidepressants in the previous month (6 weeks for fluoxetine). * Use of stimulant medication affecting dopamine release in the previous month * Use of antipsychotics in the previous month * History of neurological disease (except migraine, and PASC) based on self-report * Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report * Presence of cigarette smoking in the past two months, based on self-report * Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Positive urine drug or cotinine screen at any timepoint during the study * History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan) * Breastfeeding (for females) * Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report * Claustrophobia, based on self-report * Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns) * Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report * Severe allergic reaction to alcohol

Project neuroARTEMIS

NCT06814275
Recruiting
Conditions Stimulant Use, Human Immunodeficiency Vi...
Phase NA
Enrollment 189
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: ARTEMIS — The ARTEMIS intervention includes 5 sessions delivered individually over Zoom across 3 months. The intervention teaches 9 positive affect skills: noting and capitalizing on positive events, gratitude journaling, formal and informal mindfulness, positive reappraisal and problem solving coping skills training, focusing on personal strengths, setting achievable goals, and small acts of kindness. Each session consists of a didactic portion with in vivo skills practice, and participants are asked to complete daily home practice of the skills between sessions.
  • Behavioral: Contingency management for Antiretroviral (ARV) adherence — All participants will received the contingency management (CM) intervention to support ARV adherence. They will use the Spotlight by Scene Health platform, a HIPAA-compliant mHealth application for directly observed therapy, to upload videos of ART adherence. The app records and uploads time-stamped videos of medication doses, which staff verify asynchronously. Participants will be paid for each verified dose and receive a weekly bonus if they complete 6 doses.

Primary Outcomes

  • Neural Functional Connectivity (Month 3)
  • Neural Activation (Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-29
Completion: 2028-12-31
Eligibility
Age: 18 Years – 59 Years
Sex: ALL
Volunteers: false
Enrollment: 189 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Collaborators: Florida International University, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Christina S Meade, PhD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
  • Adam W Carrico, PhD (PRINCIPAL_INVESTIGATOR) - Florida International University
Contact Information
Study Contact:
Christina S Meade, PhD
336-716-0695
cmeade@wakehealth.edu
Sheri L Towe, PhD
336-716-4331
stowe@wakehealth.edu
Christina S Meade, PhD
336-716-0695
cmeade@wakehealth.edu
Wake Forest University School of Medicine
Interventions
  • Behavioral: ARTEMIS — The ARTEMIS intervention includes 5 sessions delivered individually over Zoom across 3 months. The intervention teaches 9 positive affect skills: noting and capitalizing on positive events, gratitude journaling, formal and informal mindfulness, positive reappraisal and problem solving coping skills training, focusing on personal strengths, setting achievable goals, and small acts of kindness. Each session consists of a didactic portion with in vivo skills practice, and participants are asked to complete daily home practice of the skills between sessions.
  • Behavioral: Contingency management for Antiretroviral (ARV) adherence — All participants will received the contingency management (CM) intervention to support ARV adherence. They will use the Spotlight by Scene Health platform, a HIPAA-compliant mHealth application for directly observed therapy, to upload videos of ART adherence. The app records and uploads time-stamped videos of medication doses, which staff verify asynchronously. Participants will be paid for each verified dose and receive a weekly bonus if they complete 6 doses.
Study Locations (1 sites)
Wake Forest University School of Medicine, Winston-Salem, North Carolina 27101 United States
Eligibility Criteria
Inclusion Criteria: * 18-59 years old * Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) * Confirmed HIV diagnosis * Current receipt of daily oral antiretroviral therapy (ART) medication * English fluency/literacy Exclusion Criteria: * Acute brain infection (e.g., neurosyphilis, toxoplasmosis) * Acutely symptomatic bipolar I or psychotic disorder * Prescription for immunomodulatory medications or other immunotherapy * Any MRI contraindications * If applicable, on antidepressant medication regimen for at least 2 months
Conditions Suicide, Attempted, Suicidal Ideation, D...
Phase NA
Enrollment 115
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: WellPATH-PREVENT — WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
  • Behavioral: Optimized WellPATH-PREVENT — The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.

Primary Outcomes

  • Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R61 (Study Entry, Week 6, Week 12)
  • Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R33 (Study Entry, Week 6, Week 12, Week 24)
  • Change in Self-Reported Affect - R61 (Study Entry, Week 6, Week 12)
  • Change in Self-Reported Affect - R33 (Study Entry, Week 6, Week 12, Week 24)
  • Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R61 (Study Entry, Week 6, Week 12)
  • Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R33 (Study Entry, Week 6, Week 12, Week 24)
  • Change in Client Satisfaction with Treatment (CSQ) - R61 (Week 6, Week 12)
  • Change in Client Satisfaction with Treatment (CSQ) - R33 (Week 6, Week 12, Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-22
Completion: 2027-09-30
Eligibility
Age: 50 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 115 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Dimitris Kiosses, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Dimitris Kiosses, PhD
914-997-4381
dkiosses@med.cornell.edu
Laurie Evans, MS
914-682-9100
lad9011@med.cornell.edu
Dimitris Kiosses, PhD
914-997-4381
dkiosses@med.cornell.edu
New York Presbyterian Hospital/Weill Cornell Medicine
Interventions
  • Behavioral: WellPATH-PREVENT — WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
  • Behavioral: Optimized WellPATH-PREVENT — The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
Study Locations (2 sites)
New York Presbyterian Hospital/Weill Cornell Medicine, New York, New York 10065 United States
Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York 10605 United States
Eligibility Criteria
Inclusion Criteria: * 50-90 years old * Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia * Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts." * We will also include patients on psychotropics and on after-care community psychotherapy. Exclusion Criteria: * Current diagnosis of Psychotic Disorders; Diagnosis of Dementia * Cognitive Impairment (MMSE ≤ 24) * Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry * Aphasia, sensory problems, and/or inability to speak English.

Taking Action for College Students

NCT06700902
Recruiting
Conditions Major Depressive Disorder, Bipolar Disor...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research is to investigate whether a peer-delivered illness self-management program called Taking Action can help college students with serious mental illnesses. Participants will be randomly assigned to either the experimental condition (Taking Action) or the control condition (information only). Participants in the experimental condition will attend five 2.5-hour Taking Action sessions. Participants will complete three interviews (baseline, post-intervention, and follow-up) to assess how well the program works, is liked, and benefits students clinically and academically. The investigators seek to test the following hypotheses: Compared to controls, students who do the Taking Action program will report greater improvements in mental health self-management attitudes, skills, and behaviors and will report greater improvements in mental health symptoms and recovery, and better academic outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Taking Action — Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.

Primary Outcomes

  • Changes from Baseline in Mental Health Symptoms (Baseline, Immediately After the Intervention, and 3-Month Follow-Up)
  • Changes from Baseline in Perceived Recovery (Baseline, Immediately After the Intervention, and 3-Month Follow-Up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-01
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Temple University
Collaborators: National Institute on Disability, Independent Living, and Rehabilitation Research
Contact Information
Study Contact:
Elizabeth Thomas, PhD
2152041699
elizabeth.thomas@temple.edu
Interventions
  • Behavioral: Taking Action — Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
Study Locations (1 sites)
Temple University, Philadelphia, Pennsylvania 19122 United States
Eligibility Criteria
Inclusion Criteria: * Currently enrolled in a 2- or 4-year postsecondary educational institution in the United States (and are able to present a valid student ID card) * Experiencing a serious mental illness, as operationalized by either: * A score of 13 or higher on the K-6 Screening Scale for serious mental illness * Self-reported psychiatric diagnosis of schizophrenia-spectrum or major affective disorder and self-reported lifetime functional impairment due to experiencing mental health challenges * 18 years of age or older * Have consistent access to a computer or smartphone and the Internet for communications * No prior WRAP or Taking Action education Exclusion Criteria: * Expected to graduate or complete their program within 2 semesters * Unable to provide informed consent
Conditions Depression in Adolescence
Phase NA
Enrollment 96
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

In this study, we will conduct a pilot RCT of a yoga-based intervention (YBI) vs. group cognitive-behavioral therapy (gCBT) at two sites. We will recruit 48 adolescent participants each in Columbus, OH and Boston, MA (96 total). We have a priori targets for indices of feasibility and acceptability, including recruitment rate, retention for assessments, class attendance, interventionist fidelity to manuals, and participant satisfaction. We hypothesize that we will meet these metrics at both sites.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Yoga-Based Intervention — This intervention consists of twice-weekly yoga classes. Classes will be led by trained yoga teachers. Each week for 12 weeks, classes will occur once in person (55 mins) and once virtually (30 mins).
  • Behavioral: group CBT — This intervention consists of twice-weekly group CBT sessions. Sessions will be led by trained behavioral health specialists. Each week for 12 weeks, sessions will occur once in person (55 mins) and once virtually (30 mins).

Primary Outcomes

  • Credibility (Start of treatment)
  • Expectancy (Start of treatment)
  • Program Satisfaction (12 weeks)
  • Class Attendance (Week 0-12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-07
Completion: 2027-12-31
Eligibility
Age: 12 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Butler Hospital
Collaborators: National Center for Complementary and Integrative Health (NCCIH), Beth Israel Deaconess Medical Center, Nationwide Children's Hospital
Principal Investigators:
  • Lisa Uebelacker, PhD (PRINCIPAL_INVESTIGATOR) - Butler Hospital
  • Shirley Yen, PhD (PRINCIPAL_INVESTIGATOR) - Beth Israel Deaconess Medical Center
Contact Information
Study Contact:
Bailey O'Keeffe, MA
401-455-6219
bokeeffe@butler.org
Julie Desaulniers
401-455-6219
jdesaulniers@butler.org
Shirley Yen, PhD
617-626-9370
syen1@bidmc.harvard.edu
Beth Israel Deaconess Medical Center
Interventions
  • Behavioral: Yoga-Based Intervention — This intervention consists of twice-weekly yoga classes. Classes will be led by trained yoga teachers. Each week for 12 weeks, classes will occur once in person (55 mins) and once virtually (30 mins).
  • Behavioral: group CBT — This intervention consists of twice-weekly group CBT sessions. Sessions will be led by trained behavioral health specialists. Each week for 12 weeks, sessions will occur once in person (55 mins) and once virtually (30 mins).
Study Locations (2 sites)
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115 United States
Nationwide Children's Hospital, Columbus, Ohio 43215 United States
Eligibility Criteria
Set A Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 10 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia; 2. Be aged 12-18; 3. Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider); 4. Be able to read and write in English; 5. Provide consent/assent appropriate to age; 6. Be able to attend group session times: 7. Have access to a private space once per week that is suitable for synchronous intervention sessions. Set A Exclusion criteria: Adolescents will be excluded if they: 1. Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia; 2. Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation; 3. Have severe depression (QIDS-A-CR score \> = 16); 4. Have moderate or high risk for suicide (Response of "yes" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months). 5. Have suicide ideation (Response of "yes" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy) 6. Are pregnant; 7. Are currently (past 4 weeks) engaged in yoga classes or in gCBT; 8. Have had substantive changes in other psychiatric treatment in the previous 4 weeks (e.g., started a new depression medication; stopped or started attending psychotherapy). 9. Have a sibling or other household member active in a study intervention (for this study) at the same time. Set B Eligibility criteria Participants who are not eligible for Set A may be enrolled in Phase 2 Set B, such that they will be eligible to attend classes but their data will not be considered in our main analyses. Set B Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 6 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia; 2. Be aged 12-18; 3. Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider); 4. Be able to read and write in English; 5. Provide consent/assent appropriate to age; 6. Be able to attend group session times: 7. Have access to a private space once per week that is suitable for synchronous intervention sessions. Set B Exclusion criteria: Adolescents will be excluded if they: 1. Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia; 2. Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation; 3. Have severe depression (QIDS-A-CR score \> = 16); 4. Have moderate or high risk for suicide (Response of "yes" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months). 5. Have suicide ideation (Response of "yes" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy) 6. Are pregnant; 7. Are currently (past 4 weeks) engaged in yoga classes or in gCBT; 8. Have a sibling or other household member active in a study intervention (for this study) at the same time.
Conditions Depression, Anxiety
Phase NA
Enrollment 93
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The present study is a randomized controlled trial that will evaluate the effect of combining two treatment components (i.e., cognitive restructuring and detached mindfulness) drawn from cognitive behavioral therapies (CBTs) that are often combined in clinical practice. However, knowledge about the effect of combining these treatment components is lacking. Therefore, this study aims to explore single, combined, and sequencing effects of these two treatment components in patients with depression and/or anxiety disorders. Furthermore, the study aims to explore possible demographic and clinical moderators of the effects to address the question of what works for whom.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mindful emotion awareness — The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With "mindful mood induction", the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With "anchoring in the present", the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file.
  • Behavioral: Cognitive flexibility — The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.

Primary Outcomes

  • Depressive symptoms (PHQ-9) (Development from pre-treatment to post-treatment (6 weeks))
  • Anxiety symptoms (BAI) (Development from pre-treatment to post-treatment (6 weeks))
  • Symptoms of generalized anxiety disorder (GAD-7) (Development from pre-treatment to post-treatment (6 weeks))
  • Symptoms of social anxiety disorder (SIAS) (Development from pre-treatment to post-treatment (6 weeks))
  • Symptoms of panic disorder (PDSS-SR) (Development from pre-treatment to post-treatment (6 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-28
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 93 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Principal Investigators:
  • Caroline Nørskov, MSc (PRINCIPAL_INVESTIGATOR) - University of Aarhus
Contact Information
Study Contact:
Caroline Nørskov, MSc
+4587150193
cn@psy.au.dk
Mia O'Toole, PhD
+4587165289
mia@psy.au.dk
Caroline Sejersbøll Nørskov, MSc
+4587150193
cn@psy.au.dk
Department of Psychology and Behavioral Sciences
Interventions
  • Behavioral: Mindful emotion awareness — The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With "mindful mood induction", the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With "anchoring in the present", the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file.
  • Behavioral: Cognitive flexibility — The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.
Study Locations (1 sites)
Department of Psychology and Behavioral Sciences, Aarhus, 8000 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. A diagnosis of an anxiety disorder (generalized anxiety disorder, social anxiety disorder, or panic disorder with or without agoraphobia) and/or mild to moderate major depressive disorder (MDD) according to DSM-5 (American Psychiatric Association, 2022). 3. Danish language proficiency. 4. Ability and willingness to give informed consent. 5. No or stable antidepressant/antianxiety medication (i.e., same dosage for ≥ 8 weeks). 6. Access to either a smartphone, tablet, or computer with video camera. Exclusion Criteria: 1. Severe depression deemed to require more intense psychotherapy or medication. 2. Persistent depressive disorder (i.e., depressive symptoms have persisted for 2 years or more). 3. Non-stabilized medication (see above). 4. Currently receiving other psychotherapy or counseling. 5. Not capable of participating online. 6. Lack of Danish proficiency. 7. A history of bipolar disorder. 8. Current or past psychosis. 9. Substance abuse or dependence judged to require treatment. 10. Suicide risk requiring immediate hospitalization.
Conditions Major Depressive Disorder (MDD), Physica...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical study is to investigate if lifestyle changes can help prevent cognitive decline and reduce depressive symptoms in people between the ages of 50 and 80 with depressive symptoms or a diagnosis of major depression, but without signs of cognitive decline. The main questions it aims to answer are: * Does regular physical activity improve mood and memory in people who are depressed or have depressive symptoms? * Does cognitive training help prevent mental difficulties in people at risk of cognitive decline? * Do changes in diet and lifestyle alter the composition of the gut microbiota and immuno-related infiammatory factors? Researchers will compare three different treatment groups to see which intervention is most effective in improving mental and cognitive health. The participants: * Will take part to online sessions on healthy eating based on the Mediterranean diet * Some will do regular exercise, supervised by a personal trainer * Others will do weekly cognitive training in small groups at the hospital * They will provide blood and fecal samples and complete cognitive tests and clinical questionnaires at the beginning, at the end of the treatment (12 weeks), and after 3 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Mediterranean Diet — Participants will receive only the educational intervention about the Mediterranean diet. The program consists of 4-5 online sessions conducted by a nutritionist.
  • Behavioral: Physical Activity — In addition to educational sessions on the Mediterranean diet, there will be 2-3 weekly personalized exercise sessions, followed by a dedicated personal trainer at a partner gym. The treatment will last 12 weeks.
  • Behavioral: Cognitive Training — In addition to educational sessions on the Mediterranean diet, there will be one weekly cognitive training session in groups, supervised by qualified staff at the IRCCS FBF. The treatment will last for 12 weeks.

Primary Outcomes

  • MADR Scale for Depression (Baseline, Week 12, and 3-month follow-up (Week 24))
  • PHQ-9 (Baseline, Week 12, and 3-month follow-up (Week 24))
  • GDS-15 (Baseline, Week 12, and 3-month follow-up (Week 24))
  • WHOQOL-BREF (Baseline, Week 12, and 3-month follow-up (Week 24))
  • RBANS (Baseline, Week 12, and 3-month follow-up (Week 24))
  • TMT (Baseline, Week 12, and 3-month follow-up (Week 24))
  • DSST (Baseline, Week 12, and 3-month follow-up (Week 24))
  • M-WCST (Baseline, Week 12, and 3-month follow-up (Week 24))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2028-03
Eligibility
Age: 50 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
Collaborators: Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), University of Milan, China Medical University, China, University College Cork, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Contact Information
Study Contact:
Elisa Mombelli
(+39) 030 35 01 598
emombelli@fatebenefratelli.eu
Moira Marizzoni, PhD
(+39) 030 35 01 563
mmarizzoni@fatebenefratelli.eu
Annamaria Cattaneo, PhD
acattaneo@fatebenefratelli.eu
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Interventions
  • Behavioral: Mediterranean Diet — Participants will receive only the educational intervention about the Mediterranean diet. The program consists of 4-5 online sessions conducted by a nutritionist.
  • Behavioral: Physical Activity — In addition to educational sessions on the Mediterranean diet, there will be 2-3 weekly personalized exercise sessions, followed by a dedicated personal trainer at a partner gym. The treatment will last 12 weeks.
  • Behavioral: Cognitive Training — In addition to educational sessions on the Mediterranean diet, there will be one weekly cognitive training session in groups, supervised by qualified staff at the IRCCS FBF. The treatment will last for 12 weeks.
Study Locations (1 sites)
IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, 25125 Italy
Eligibility Criteria
Inclusion Criteria: * Aged between 50 and 80 years; * Diagnosis of DDM according to DSM-5 or depressive symptoms (PHQ-9 or GDS-15 ≥ 5, the choice of test will be justified by the participant's age); * Ability to provide written informed consent. Exclusion Criteria: * Active gastrointestinal disorders; * Autoimmune disorders; * Chronic inflammatory disorders; * Diagnosis of dementia; cognitive impairment or mild functional impairment. * Use of antibiotics and/or anti-inflammatory drugs in the 8 weeks prior to the screening visit.
Conditions Treatment-resistant Depression (TRD)
Phase EARLY_PHASE1
Enrollment 5
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to optimize the target brain areas for deep brain stimulation (DBS) for depression based on personalized brain imaging and stereo-electroencephalography(SEEG), to administer long-term DBS treatment in the target brain areas, to assess the effectiveness and safety of DBS for refractory depression and to validate the method of personalized optimization of DBS targets. The main questions it aims to answer are: 1. Where is the optimal DBS target brain region for each patient? 2. What are the optimal DBS parameters for each patient ? 3. What are the neural biomarkers of depression symptoms for each patient? 4. Are the optimized DBS strategies effective in treating refractory depression?

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Deep Brain Stimulation(DBS) — During the DBS treatment phase, the DBS device will apply electrical stimulation to the patient's target brain regions using a specific strategy, and if the efficacy of this phase is not satisfactory, electrical stimulation will continue to be applied during the efficacy observation phase after DBS shutdown.
  • Drug: Esketamine — SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.

Primary Outcomes

  • Change in Hamilton Rating Scale for Depression (HAMD) score during the DBS treatment phase relative to preoperative baseline (at baseline and after 442 day)
  • Changes in HAMD scores during the efficacy observation phase after DBS shutdown (Two months after 442 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-01-05
Completion: 2028-12-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 5 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Junming Zhu, Ph.D.
+86 13968055768
dr.zhujunming@zju.edu.cn
Yuxiao Yang, Ph.D.
+86 15088771810
yuxiao.yang@zju.edu.cn
The Second Affiliated Hospital of Zhejiang University School of Medicine
Interventions
  • Device: Deep Brain Stimulation(DBS) — During the DBS treatment phase, the DBS device will apply electrical stimulation to the patient's target brain regions using a specific strategy, and if the efficacy of this phase is not satisfactory, electrical stimulation will continue to be applied during the efficacy observation phase after DBS shutdown.
  • Drug: Esketamine — SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.
Study Locations (1 sites)
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: 1. A psychiatrist-confirmed diagnosis of major depressive disorder in accordance with the Diagnostic And Statistical Manual Of Mental Disorders.5th Ed (DSM-V); 2. A psychiatric examination by two trained psychiatrists and a diagnosis consistent with the DSM-V; 3. A history of depression of at least 12 months duration in depressed patients (including MECT) who have failed to respond to a full dose and course of treatment with 2 or more antidepressants of different mechanisms; 4. A 17-item score on the HAMD scale ⩾ 20 at initial screening; 5. A score of ≤ 50 on the Gross Assessment of Functioning (GAF) scale; 6. The patient himself/herself or legal guardian was able to fully understand the therapy and agreed to enroll after signing an informed consent form. Exclusion Criteria: 1. Persons with severe or unstable cardiac, hepatic, renal, endocrine, hematologic, and other medical disorders and co-morbidities with psychotic symptoms, including personality disorders diagnosed by history, questioning, and clinical examination; 2. Persons with psychiatric disorders other than depression (except generalized anxiety); 3. Persons with a history of substance abuse within 12 months; persons with a previous history of epilepsy, and persons with febrile convulsions in childhood; 4. Patients with a history of suicide attempts within the past 6 months or more than 2 suicide attempts within the past 2 years; 5. Women who are breastfeeding, pregnant, and patients who are pregnant or intend to become pregnant during the clinical study; 6. Contraindications to DBS surgery and MRI; 7. Years of education less than or equal to 9 years; 8. Patients who are involuntarily hospitalized.
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 200
Locations 18 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: NBI-1065845 — NBI-1065845 tablets
  • Drug: Placebo — Matching placebo tablets

Primary Outcomes

  • Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56 (Baseline, Day 56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-22
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neurocrine Biosciences
Principal Investigators:
  • Clinical Development Lead (STUDY_DIRECTOR) - Neurocrine Biosciences
Contact Information
Study Contact:
Neurocrine Medical Information Call Center
1-877-641-3461
medinfo@neurocrine.com
Interventions
  • Drug: NBI-1065845 — NBI-1065845 tablets
  • Drug: Placebo — Matching placebo tablets
Study Locations (18 sites)
Neurocrine Clinical Site, Little Rock, Arkansas 72204 United States
Neurocrine Clinical Site, Garden Grove, California 92844 United States
Neurocrine Clinical Site, Orange, California 92866 United States
Neurocrine Clinical Site, Pico Rivera, California 90660 United States
Neurocrine Clinical Site, San Diego, California 92103 United States
Neurocrine Clinical Site, Upland, California 91786 United States
Neurocrine Clinical Site, Hollywood, Florida 33024 United States
Neurocrine Clinical Site, Maitland, Florida 32751 United States
Neurocrine Clinical Site, Boston, Massachusetts 02116 United States
Neurocrine Clinical Site, Watertown, Massachusetts 02472 United States
Eligibility Criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.
Conditions Chemotherapy Induced Peripheral Neuropat...
Phase PHASE2, PHASE3
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of chemotherapy (CT), often requiring dose reductions or treatment interruptions, which can compromise efficacy of the planned CT (limiting its efficacy). Additionally, CIPN usually decreases patients' quality of life. Unfortunately, effective treatments for CIPN are limited. Emerging evidence suggests potential benefits of rectal ozone therapy and points to a possible role of the gut microbiome in CIPN development and treatment response. This observational study, ancillary to the randomized clinical trial (RCT) OzoParQT (NCT06706544), investigates the relationship between gut microbiome composition and CIPN severity in patients receiving rectal ozone therapy. Primary Objectives: To evaluate if gut microbiome profiles differ between patients: 1. with and without symptomatic improvement of CIPN. 2. receiving rectal ozone therapy and those receiving placebo. Secondary Objectives: To evaluate the relationship between gut microbiome composition and: 1. Health-related quality of life, 2. Anxiety and depression, 3. Biochemical markers of oxidative stress and inflammation. Main Trial Endpoints. Changes from baseline at the end of ozone therapy (week 16) in: * Gut microbiome profile * Patient-reported numbness and tingling * Neuropathy severity (QLQ-CIPN20 scale) * Paresthesia toxicity grade (CTCAE v.5.0) Secondary Trial Endpoints. Changes from baseline at the end of ozone therapy (week 16) in: * Patient-reported quality of life (EQ-5D-5L questionnaire) * Quality of life (QLQ-C30 questionnaire) * Anxiety and depression levels (HADS questionnaire) * Biochemical markers of oxidative stress * Biochemical markers of inflammation Trial Design: This observational study will analyze data from patients enrolled in the randomized, triple-blind, placebo-controlled OzoParQT clinical trial (NCT06706544). Trial Population in the OzoParQT trial (NCT06706544): Adults (≥18 years) with any tumor type, experiencing CIPN-related paresthesias (numbness and/or tingling), with a toxicity grade ≥ 2 according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0) for ≥ 3 months. Intervention in the OzoParQT trial (NCT06706544). All patients will receive standard care for their CIPN symptoms plus 40 sessions of rectal insufflation of an O3/O2 gas mixture over 16 weeks: * Ozone group: O3/O2 concentration increasing from 10 to 30 µg/mL * Control-placebo group: O2 only (0 µg/mL O3) Study Duration: Each patient will participate in this study (OzoParQTmicrob) for 16 weeks, concurrent with the ozone therapy intervention. The total planned project duration is 60 months.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Ozone therapy — Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
  • Drug: Oxygen (placebo) — Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

Primary Outcomes

  • Change from baseline in gut microbiome profile, at the end of ozone therapy. (16 weeks.)
  • Change from baseline in "numbness and tingling" self-perceived by patients at the end of ozone treatment. (16 weeks.)
  • Changes from baseline in the degree of neuropathy according to the QLQ-CIPN20 scale at the end of ozone treatment. (16 weeks.)
  • Changes from baseline in the Grade of toxicity of parestesias (numbness, tingling) according to the CTCAE v.5.0. scale at the end of ozone treatment. (16 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2025-02-07
Completion: 2030-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bernardino Clavo, MD, PhD
Collaborators: Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Instituto de Salud Carlos III, Council of Gran Canaria, Centers for International Business Education and Research, Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna
Principal Investigators:
  • Bernardino Clavo, MD, PhD (STUDY_CHAIR) - Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • Francisco Rodríguez-Esparragón, BSc, PhD (STUDY_DIRECTOR) - Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • Jacob Lorenzo-Morales, Prof (PRINCIPAL_INVESTIGATOR) - Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias - Universidad de La Laguna (IUETSPC-ULL)
Contact Information
Study Contact:
Bernardino Clavo, MD, PhD
34928449278
bernardinoclavo@gmail.com
Francisco Rodríguez-Esparragón, BSc, PhD
34928449288
afrodesp@gmail.com
Bernardino Clavo, MD, PhD
34928449278
bernardinoclavo@gmail.com
Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
Interventions
  • Drug: Ozone therapy — Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
  • Drug: Oxygen (placebo) — Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study Locations (1 sites)
Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Las Palmas 35019 Spain
Eligibility Criteria
Inclusion Criteria: * 0\. Patients who agree to participate in the randomized clinical trial OzoParQT, and who also agree to participate in this study of gut microbiota by providing stool samples. * 1\. Adults \> = 18 years old. * 2\. Previous treatment with any chemotherapy because of any tumor. * 3\. Clinical diagnosis of paresthesia (numbness, tingling) secondary to CIPN, with toxicity Grade \> = 2 (according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0) for \> = 3 months. * 4\. Without neurotoxic chemotherapy \> = 3 months. * 5\. Cancer disease is stable or in remission. * 6\. Life expectancy \> = 6 months. * 7\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from 14 days before the first ozone therapy session up to 14 days after the last one. * 8\. To sign and date the specific informed consent of both studies (OzoParQT and OzoParQTmicrob) Exclusion Criteria: * 1\. Age \< 18 years. * 2\. A woman who is lactating, pregnant, suspected of being pregnant, or a woman of childbearing potential who does not use adequate contraceptive methods. * 3\. Suspected symptoms are due to diabetic or compressive neuropathy. * 4\. Severe psychiatric disorders. * 5\. Inability to complete the quality of life questionnaires. * 6\. Elevation above 5 times the maximum limit of normal creatinine. * 7\. Patient who is hemodynamic or clinically unstable or who requires urgent or short-term interventional measures. * 8\. Neoplasia in progression requiring recent initiation of systemic treatment or maintenance with neurotoxic chemotherapy. * 9\. Life expectancy (for any reason) \< 6 months. * 10\. Known allergy to ozone, known glucose 6 phosphate dehydrogenase (G6PD) deficiency, or hemochromatosis. * 11\. Contraindications or impossibility for rectal ozone treatment or to attend regularly to the treatment. * 12\. Not meeting each and every one of the inclusion criteria
Conditions Depressive Disorder, Major
Phase PHASE3
Enrollment 1000
Locations 181 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Brenipatide — Administered SC
  • Drug: Placebo — Administered SC

Primary Outcomes

  • Time to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD) (From Randomization in Double-Blind Adjunctive Treatment to First Relapse For at Least 12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-09
Completion: 2028-02
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
747-998-0394
Accellacare - Moorpark
Interventions
  • Drug: Brenipatide — Administered SC
  • Drug: Placebo — Administered SC
Study Locations (181 sites)
Accellacare - Moorpark, Moorpark, California 93021 United States
ATP Clinical Research, Orange, California 92866 United States
Yale University School of Medicine, New Haven, Connecticut 06519 United States
Encore Medical Research, Hollywood, Florida 33024 United States
K2 Medical Research - Maitland, Maitland, Florida 32751 United States
Life Medical Research Group Corp, Miami Gardens, Florida 33014 United States
Floridian Clinical Research, LLC, Miami Lakes, Florida 33016-1518 United States
CLA Research, Naples, Florida 34116 United States
Optimal Research Sites, Orange City, Florida 32763 United States
Charter Research - Orlando, Orlando, Florida 32803 United States
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic criteria for major depressive disorder * Are on a stable standard of care medication for major depressive disorder * Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as * self-inject study intervention * store and use the provided blinded study intervention, as directed * maintain electronic and paper study diaries, as applicable, and * complete the required questionnaires Exclusion Criteria: * Have a lifetime history or current diagnosis of the following: * schizophrenia or other psychotic disorder * bipolar disorder * borderline personality disorder, or * any eating disorder. * Have type 1 diabetes mellitus, or a history of * ketoacidosis, or * hyperosmolar state or coma. * Evidence of moderate or severe substance or alcohol use disorder within 180 days of screening * Are actively suicidal or deemed a significant risk for suicide * Have participated in a clinical study and received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening